Streetbeat News

DLO

DLocal Limited

https://www.dlocal.com

Industry

Software - Infrastructure

DLocal Limited operates a payments platform in the United States, Europe, China, and internationally. Its payments platform enables merchants to get paid and to make payments online. The company serves commerce, streaming, ride-hailing, financial services, advertising, software as a service, travel, e-learning, on-demand delivery, gaming, and crypto industries. DLocal Limited was founded in 2016 and is headquartered in Montevideo, Uruguay.

Open

10.30

Mkt cap

2.8B

Volume

2.3M

High

10.35

P/E Ratio

22.48

52-wk high

19.45

Low

9.61

Div yield

N/A

52-wk low

6.58

The article highlights three oversold financial stocks with RSI values near or below 30, indicating potential buying opportunities. The stocks mentioned are Fundamental Global Inc. (FGF), Granite Point Mortgage Trust Inc. (GPMT), and DLocal Limited (DLO).

Portfolio Pulse from Avi Kapoor

May 20, 2024 | 11:03 am

DLocal (NASDAQ:DLO) has been analyzed by 10 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is now $18.0, down from $19.75. Recent analyst actions include several downgrades and lowered price targets.

Portfolio Pulse from Benzinga Insights

May 16, 2024 | 5:00 pm

B of A Securities analyst Jason Kupferberg maintains a Neutral rating on DLocal (NASDAQ:DLO) but lowers the price target from $18 to $15.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 4:56 pm

Bolt Biotherapeutics shares fell 34% after reporting a GAAP loss of 28 cents per share on $5.30 million in sales. Analysts from Guggenheim and Stifel downgraded the stock. Other stocks like AERWINS Technologies and Sintx Technologies saw significant gains, while Virpax Pharmaceuticals and Yield10 Bioscience experienced notable losses.

Portfolio Pulse from Avi Kapoor

May 15, 2024 | 5:38 pm

DLocal Ltd (NASDAQ:DLO) shares are plunging after the company reported weaker-than-expected earnings for Q1. The company missed analyst estimates for both EPS and sales, despite showing year-over-year growth in revenue and total payment volume. Goldman Sachs and Susquehanna have maintained their ratings but lowered their price targets.

Portfolio Pulse from Dylan Berman

May 15, 2024 | 4:02 pm

MuddyWatersResearch posted on X (formerly Twitter) about the potential for fraud in the company DLocal Limited (DLO), suggesting that in a world without enforcement, fraudulent activities can take a long time to be exposed.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 1:25 pm

Arcutis Biotherapeutics (NASDAQ:ARQT) shares surged 29% in pre-market trading after reporting better-than-expected Q1 earnings and sales. Other notable pre-market movers include Faraday Future Intelligent Electric (NASDAQ:FFIE), Sintx Technologies (NASDAQ:SINT), and Dolphin Entertainment (NASDAQ:DLPN) among gainers, while Virpax Pharmaceuticals (NASDAQ:VRPX) and Bolt Biotherapeutics (NASDAQ:BOLT) led the decliners.

Portfolio Pulse from Avi Kapoor

May 15, 2024 | 12:14 pm

Goldman Sachs analyst Tito Labarta maintains a Buy rating on DLocal (NASDAQ:DLO) but lowers the price target from $18 to $16.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:22 am

Susquehanna analyst James Friedman maintains a Positive rating on DLocal (NASDAQ:DLO) and keeps the price target at $21.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:18 am

dLocal shares are trading lower following a report of weaker-than-expected Q1 earnings and an indication that the company may hit the lower end of its guidance range.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:04 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.